8-K: TransCode Completes Phase 1a Trial for TTX-MC138

TransCode Therapeutics announced the successful completion of its Phase 1a clinical trial for TTX-MC138, achieving its primary safety endpoint and defining a recommended Phase 2 dose.

Summary

• The Phase 1a clinical trial for TTX-MC138, an investigational inhibitor of microRNA-10b, has been completed.
• The primary safety endpoint was achieved, and a recommended Phase 2 dose (RP2D) has been established.
• Sixteen patients with advanced solid tumors were treated across four escalating dose levels.
• No significant treatment-related safety events or dose-limiting toxicities were observed.
• The median treatment duration was 4 months, with a range of 2 to 12 months, and three patients remain on trial.
• 44% (7 out of 16) patients were classified as having stable disease lasting 4 months or longer, based on RECIST data.
• One patient with thyroid cancer demonstrated a reversal of increasing thyroglobulin levels, presenting with undetectable levels at the most recent measurement.
• Positive pharmacodynamic effects were observed over all four administered dose range levels, consistent with preclinical models and the Phase 0 clinical trial.
• Preliminary data will be presented in a poster session at the ESMO Congress from October 17-21, 2025, in Berlin, Germany (FPN: 983P).
• The trial's NCT Identifier is NCT06260774.

Sentiment

Score: 8

Explanation: The successful completion of a Phase 1a trial, meeting its primary safety endpoint, establishing a Phase 2 dose, and showing early signs of efficacy (stable disease, specific patient response) are significant positive milestones for a clinical-stage biotechnology company, despite the inherent risks of drug development.

Positives

• Primary safety endpoint for TTX-MC138 was successfully achieved.
• No significant treatment-related safety events or dose-limiting toxicities were observed across all dose levels.
• A recommended Phase 2 dose (RP2D) has been established, enabling advancement to a Phase 2a clinical trial.
• 44% (7 out of 16) patients demonstrated stable disease lasting 4 months or longer, indicating early signs of clinical benefit.
• One thyroid cancer patient showed a compelling reversal of increasing thyroglobulin levels, reaching undetectable levels during treatment.
• The median treatment duration of 4 months, with some patients remaining on trial for up to 12 months, suggests good tolerability and potential disease control.
• Positive pharmacodynamic effects were observed, consistent with prior preclinical and Phase 0 clinical trial data.
• The safety and durability profile is consistent with the known mechanism of action of TTX-MC138.

Risks

• Risks associated with drug discovery and development.
• The risk that results of clinical trials will not be consistent with preclinical studies, expectations, or previous clinical trials.
• Risks associated with the conduct of clinical trials.
• Risks associated with financial condition and the need to obtain additional funding to support business activities, including the ability to continue as a going concern.
• Risks associated with the timing and outcome of planned regulatory submissions.
• Risks associated with obtaining, maintaining, and protecting intellectual property.
• Risks associated with the ability to enforce patents against infringers and defend the patent portfolio against challenges from third parties.
• Risks of competition from other companies developing products for similar uses.
• Risks associated with dependence on third parties.
• Risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions.

Future Outlook

The company plans to advance TTX-MC138 into a Phase 2a clinical trial to assess its efficacy across selected metastatic diseases and for multiple indications, leveraging the established recommended Phase 2 dose. Further plans include a final clinical study report, scientific presentations, and publications. Management believes these findings position the company to potentially intervene earlier in patients' disease, offering a new therapeutic option for those at risk of developing metastatic disease.

Management Comments

• William McKean, MD, PhD (The START Center for Cancer Research) stated: "The clinical benefit we are observing in patients treated with TTX-MC138 is compelling given the pre-clinical data and length of time the drug remains in the tumor cells."
• Daniel Vlock, MD, Consulting Clinician (TransCode) noted: "The observed safety profile, coupled with the durability of TTX-MC138's anti-tumor effects, is particularly encouraging. These findings are consistent with the drug's mechanism of action and provide a basis for a more rigorous efficacy evaluation. This positions us to potentially intervene earlier in the patients disease, offering a new therapeutic option for patients at risk of developing metastatic disease."

Industry Context

The successful completion of a Phase 1a trial for TTX-MC138, an antisense oligonucleotide (ASO) targeting microRNA-10b, positions TransCode Therapeutics within the growing field of targeted cancer therapies and immuno-oncology. The focus on metastatic disease, a significant challenge in cancer treatment, and the exploration of microRNA inhibition as a therapeutic modality, align with broader industry trends seeking novel and more precise treatments for advanced malignancies.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial progression, potentially increasing company valuation and future prospects.
• Patients: Potential for a new therapeutic option for metastatic cancer, especially those overexpressing microRNA-10b.
• Employees: Positive impact on morale and job security due to successful research and development progress.
• Regulatory Authorities: Will review future submissions for Phase 2a and subsequent clinical development stages.

Next Steps

• Initiate a Phase 2a clinical trial for TTX-MC138 to assess efficacy across selected metastatic diseases and for multiple indications.
• Present preliminary data from the Phase 1a trial at the ESMO Congress from October 17-21, 2025.
• Plan for a final clinical study report, scientific presentations, and publications based on the Phase 1a data.

Key Dates

Recommendation

While the Phase 1a results are positive, demonstrating safety and early signs of efficacy, the company is still in early-stage clinical development. Significant risks remain, including the explicit mention of the need for future funding and the uncertain outcomes of larger efficacy trials (Phase 2a and beyond). A 'Hold' recommendation acknowledges the positive progress while recognizing the long and risky path ahead for drug development. It is too early for a 'Buy' given the early stage and inherent risks, but the positive data prevents a 'Sell'.

Keywords

TransCode Therapeutics, RNAZ, TTX-MC138, Phase 1a clinical trial, metastatic cancer, microRNA-10b inhibitor, oncology, drug development, biotechnology, ESMO, stable disease, safety endpoint, thyroglobulin